Current Report Filing (8-k)
July 27 2017 - 4:08PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of report (Date of earliest event reported):
July 26, 2017
AYTU BIOSCIENCE, INC.
|
(Exact Name of Registrant as Specified in Charter)
|
|
|
|
Delaware
|
000-53121
|
47-0883144
|
(State or Other Jurisdiction
of Incorporation)
|
(Commission
File Number)
|
(IRS Employer
Identification No.)
|
|
|
|
373 Inverness Parkway, Suite 206, Englewood, Colorado
|
80112
|
(Address of Principal Executive Offices)
|
(Zip Code)
|
Registrant’s Telephone Number, Including
Area Code:
(720) 437-6580
Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions
(
see
General Instruction A.2. below):
|
¨
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
¨
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act.
¨
|
Item 5.07
|
Submission of Matters to a Vote of Security Holders.
|
A special meeting of stockholders of
Aytu BioScience, Inc. was held on July 26, 2017.
At the meeting, our stockholders took the
following actions:
|
1.
|
Approved an amendment to our Certificate of Incorporation
to effect a reverse stock split at a ratio of any whole number up to 1-for-20, as determined by our board of directors, at any
time before November 14, 2018 (or such other date that is one year after the date of our 2018 annual meeting of stockholders),
if and as determined by our board of directors. The vote was 9,707,984 for, 1,580,963 against, 97,749 shares abstaining and no
broker non-votes.
|
|
2.
|
Approved an amendment to our 2015 Stock Option and Incentive
Plan to (i) increase the number of authorized shares of common stock reserved for issuance
thereunder from 2,000,000 to 3,000,000, (ii) increase the number of shares that may be issued as incentive stock options from
2,000,000 to 3,000,000, (iii) increase the maximum number of shares of common stock (A) underlying stock options or stock
appreciation rights that may be granted to any one individual during any calendar year period, and (B) granted to any one individual
that is intended to qualify as “performance-based compensation” under Section 162(m) of the Internal Revenue Code
of 1986, as amended, for any performance cycle from 1,000,000 to 2,000,000, and (iv) in the event that we effect a reverse stock
split prior to November 14, 2018 (or such other date that is one year after the date of our 2018 annual meeting of stockholders),
immediately after the effective time of such reverse stock split, (A) the maximum number of shares reserved under the Plan will
be automatically increased to 3,000,000, (B) the maximum number of shares that may be issued pursuant to any type of award will
be automatically increased to 3,000,000, (C) the number of shares that may be granted to any one individual during any one calendar
year period as stock options or stock appreciation rights will be automatically increased to 2,000,000, and (D) the number of
shares that may be issued in the form of incentive stock options will be automatically increased to 3,000,000. The vote was 6,377,095
for, 630,660 against, 26,123 shares abstaining and 4,352,818 broker non-votes.
|
|
Item 9.01
|
Financial Statements and Exhibits.
|
|
10.1
|
2015 Stock Option and Incentive Plan, as amended on July
26, 2017.
|
SIGNATURE
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: July 27, 2017
|
AYTU BIOSCIENCE, INC.
|
|
|
|
|
|
|
|
|
/s/ Gregory A. Gould
|
|
|
Name: Gregory A. Gould
Title: Chief Financial Officer
|
|
AYTU BioPharma (NASDAQ:AYTU)
Historical Stock Chart
From Mar 2024 to Apr 2024
AYTU BioPharma (NASDAQ:AYTU)
Historical Stock Chart
From Apr 2023 to Apr 2024